Fda's otat in agreement with 12-month reduction in pain as primary endpoint for chronic low back pain program

New york, dec. 15, 2021 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received feedback from the us food & drug administration's (fda) office of tissues and advanced therapies (otat) on the phase 3 program of rexlemestrocel-l in patients with chronic low back pain (clbp) due to degenerative disc disease (ddd) refractory to available therapies, including opioids.
MESO Ratings Summary
MESO Quant Ranking